Background
==========

Alternative pre-mRNA splicing endows genes with the potential to produce a menagerie of protein products. After pre-mRNA is transcribed, a complex system of regulation determines which one of several possible versions of mature mRNA will be produced (reviewed in \[[@B1]\]). Alternative splicing is particularly important in human gene expression, as it affects half or more of human genes \[[@B2],[@B3]\]. The diversity-generating capacity of alternative splicing can be staggering: one notable example, the *dscam*gene of *Drosophila melanogaster*, is hypothetically capable of producing 38,016 unique alternative isoforms \[[@B4]\]. However, functional roles for most alternative isoforms remain undiscovered.

It has been known for more than a decade that nonsense and frameshift mutations that induce premature termination codons can destabilize mRNA transcripts *in vivo*\[[@B5],[@B6]\]. First investigated in yeast and humans, NMD was subsequently observed in a wide range of eukaryotes and is now thought to occur in all eukaryotes \[[@B7]\]. How cells manage to distinguish a premature termination codon from a normal termination codon has been the subject of intense investigation. Important details have emerged that establish the following mechanistic framework model for NMD in mammals (Figure [1](#F1){ref-type="fig"}).

During pre-mRNA processing, the spliceosome removes intron sequences. As this occurs, a set of proteins called the exon-junction complex is deposited 20-24 nucleotides upstream of the sites of intron removal \[[@B8]-[@B11]\]. The components of this complex serve the dual roles of facilitating export of the mature mRNA to the cytoplasm and remembering the gene structure \[[@B12]\]. According to the current model, as a ribosome traverses the mRNA in its first pioneering round of translation, it displaces all exon-junction complexes in its path \[[@B13]-[@B16]\]. For normal mRNAs, whose termination codons are on or near the final exon, the ribosome will have displaced all exon-junction complexes. By contrast, if any exon-junction complexes remain when the ribosome reaches the stop codon, a series of interactions ensues that leads to the decapping and degradation of the mRNA. This model explains the basis of the \'50 nucleotide rule\' for mammalian NMD: if a termination codon is more than about 50 nucleotides upstream of the final exon, it is a PTC and the mRNA that harbors it will be degraded \[[@B17]\]. The mechanisms for NMD differ among yeast \[[@B18]\], flies \[[@B19]\], and mammals - and may be different still in other eukaryotes.

Degradation of PTC^+^mRNAs is generally thought to occur as a quality-surveillance system -preempting translation of potentially dominant-negative, carboxy-terminal truncated proteins \[[@B20]\]. PTC^+^transcripts are aberrantly produced in several ways. The somatic recombination that underlies immune-system diversity frequently generates recombined genes whose transcripts contain a PTC \[[@B21]\]. Inefficient or faulty splicing will often generate a frameshift in the resulting mRNA, inducing a PTC to come into frame. Also, the high processivity of RNA polymerase yields a relatively high error rate, 1 in 10,000 bases \[[@B22],[@B23]\], commonly introducing premature stops. DNA mutations are a source of potentially heritable PTCs. It is estimated that 30% of inherited disorders in humans are caused by a PTC \[[@B24]\]. The numerous diseases whose pathogenesis has been linked to NMD-inducing PTC mutations include aniridia due to the *PAX6*gene \[[@B25]\], Duchenne muscular dystrophy due to the *dystrophin*gene \[[@B26]\], and Marfan syndrome due to the *FBN1*gene \[[@B27]\].

In addition to its quality-control role in degrading aberrantly produced PTC^+^mRNAs, NMD has also been shown experimentally to act on a handful of wild-type PTC^+^mRNAs \[[@B28]-[@B35]\]. In *Caenorhabditis elegans*, for example, expression of the ribosomal proteins L3, L7a, L10a and L12 and the SR proteins SRp20 and SRp30b are regulated posttranscriptionally via the coupling of alternative splicing and NMD \[[@B31],[@B32]\]. In each case, productive isoforms were shown to be produced *in vivo*, as well as unproductive isoforms with a PTC. Regulated splicing to generate the unproductive isoforms is used as a means of downregulating protein expression, as these mRNA isoforms are degraded by NMD rather than translated to make protein. This system, which we have termed regulated unproductive splicing and translation (RUST), is also used in humans \[[@B28]-[@B30]\]. For example, the SR protein SC35 has been shown to autoregulate its own expression using RUST \[[@B29]\]. When levels of SC35 protein are elevated, SC35 binds its own pre-mRNA, inducing the production of PTC^+^*SC35*mRNA. The PTC^+^*SC35*mRNA is destabilized by NMD, resulting in lower levels of SC35 protein. A similar autoregulatory RUST system was also recently discovered to control production of polypyrimidine tract binding protein (PTB) \[[@B35]\].

In a previous study, we found that 35% of human mRNA alternative isoforms reliably inferred from expressed sequence tags (ESTs) are PTC^+^, rendering them apparent targets of NMD (see \[[@B36]\] and a conference report at \[[@B37]\]. Therefore, many wild-type alternative mRNA isoforms may not be translated into functional protein, but instead are targeted for degradation by NMD. The vast majority of PTC^+^isoforms identified in that study represent previously unrecognized potential targets of NMD. However, EST databases contain expressed sequence for many isoforms that are otherwise uncharacterized. Therefore, it was not obvious how many of the isoforms identified in that study as PTC^+^were functionally relevant or even previously known. It was also not obvious to what extent those PTC^+^isoforms represented instances of RUST regulation or simply errors or deregulation in pre-mRNA processing. Regardless, it is clear that NMD has a vital role in regulating mammalian gene expression, as inhibition of NMD is embryonic lethal for mouse \[[@B38]\].

To understand the biological significance of PTC^+^isoforms and the prevalence of NMD on wild-type transcripts, it is necessary to expand beyond existing isolated RUST examples, while retaining a focus on functionally characterized genes. For this reason, we analyzed the human alternative isoforms described in the SWISS-PROT database. Common routes for gene isoform sequences to be determined and entered into databases include the cloning of intronless mini-genes and the sequencing of unexpected PCR bands. By either method, gene structure cannot be directly observed, and therefore PTCs may be overlooked. Further computational and experimental analyses will also often be oblivious to these features. Because the cloning and characterization of many isoforms predates our current understanding of NMD action, we hypothesized that unrecognized potential targets of NMD may be present even in curated databases like SWISS-PROT. We found that many of these alternative protein isoforms derive from PTC^+^mRNAs. This is particularly surprising as SWISS-PROT is a heavily curated database of expressed protein sequences. According to the current NMD model, these PTC^+^mRNAs should be degraded, and therefore the protein isoforms should not be expressed at high abundance. To resolve this apparent conflict, we examined existing experimental evidence and found that, in several cases, results described in the scientific literature are readily explained by NMD action.

Results and discussion
======================

SWISS-PROT protein isoforms from PTC^+^mRNAs
--------------------------------------------

We examined the human alternative isoforms described in the SWISS-PROT database \[[@B39]\] to determine if any derive from PTC^+^mRNA (see Materials and methods). For each alternative human protein isoform sequence in SWISS-PROT, we attempted to identify a corresponding cDNA/mRNA sequence in GenBank \[[@B40]\] or RefSeq \[[@B41]\]. As shown in Figure [2](#F2){ref-type="fig"}, 2,742 isoform sequences from 1,463 SWISS-PROT entries could be reliably mapped to a cDNA/mRNA sequence. Next, we aligned each cDNA/mRNA sequence to the corresponding region of genome sequence using the SPIDEY program \[[@B42]\]. The SPIDEY output was analyzed to identify the position of introns in each gene. To determine which cDNA/mRNA sequences have PTCs according to the 50-nucleotide rule for NMD, the position of the termination codon as reported in each GenBank or RefSeq file was compared to the position of the introns. Of 2,483 alternative isoforms from 1,363 SWISS-PROT entries that passed quality filters, 144 isoforms (5.8% of 2,483) from 107 entries (7.9% of 1,363) were found to have PTCs, making them candidate targets of NMD. We also found that SWISS-PROT entries that contain multiple alternative isoforms amenable to our analysis were more likely to contain at least one PTC^+^isoform (see Figure [3](#F3){ref-type="fig"}). The complete list of PTC^+^alternative isoforms we identified in this analysis, along with their SWISS-PROT accession numbers and cDNA/mRNA identifiers, are shown in Table [1](#T1){ref-type="table"}. The SPIDEY alignments for each of the isoforms we identified as PTC^+^are provided as Additional data file 1.

Next we examined existing reports for experimental evidence that would refute or support action of NMD on these PTC^+^isoforms. We found that published descriptions of these PTC^+^isoforms sometimes do describe the isoforms as containing premature termination codons. However, these articles almost universally lack any mention of NMD, even as they often describe data that is suggestive of NMD action. Among the many well-characterized proteins found in our study to have at least one PTC^+^splice variant, three examples demonstrate how previously published experimental results may be interpreted in the light of NMD degradation of alternative mRNA isoforms.

Calpain-10
----------

Calpain-10 is an ubiquitously expressed protease that is alternatively spliced to produce eight mRNA isoforms \[[@B43]\], found in SWISS-PROT as Q9HC93. The gene for calpain-10 has been intensively studied because a polymorphism in its third intron, UCSNP-43, has been linked to type II diabetes in several populations. Because this polymorphism lies in intronic sequence it does not directly affect the coding potential of any isoform of calpain-10. It was shown that homozygosity of UCSNP-43 leads to reduced levels of total calpain-10 transcript and is coincident with insulin resistance in skeletal muscle \[[@B44]\]. Previous investigations into how this polymorphism affects transcript abundance have centered on transcriptional regulation \[[@B43],[@B45]\]. In an expression study, Horikawa *et al*. found four of the eight isoforms to be \"less abundant\". In our SWISS-PROT survey we found these same four mRNA isoforms to be PTC^+^, suggesting that NMD may be responsible for this experimental observation (Figure [4](#F4){ref-type="fig"}). This introduces the possibility that UCSNP-43 may affect the regulation of calpain-10 alternative splicing, favoring production of one or more of the PTC^+^isoforms.

CDC-like kinases CLK1, CLK2 and CLK3
------------------------------------

CLK1, CLK2 and CLK3 - three members of the CDC-like kinase family (also known as LAMMER kinases and STY kinases; SWISS-PROT entries P49759, P49760, P49761) - were found to have at least one PTC^+^splice variant. CLKs are thought to be high-level regulators of alternative splicing, as CLK1 has been shown to activate a set of SR proteins by phosphorylating them \[[@B46]-[@B48]\]. The pattern of alternative splicing of each CLK paralog was found to be the same: a full-length isoform and an isoform that skips exon 4 \[[@B49]\]. We found that in each case, skipping exon 4 induces a frameshift that creates a PTC (Figure [5a](#F5){ref-type="fig"}). The conceptual translations of these PTC^+^isoforms, described as \'truncated,\' lack most of the coding region, including the kinase domain.

Having observed conservation amongst the human paralogs, we examined the gene structures of the mouse orthologs of each CLK (Figure [5b](#F5){ref-type="fig"}) to determine if the splicing pattern was shared across species. We identified mouse orthologs through existing RefSeq database annotation. EST evidence of alternative splicing showed that all three mouse CLK orthologs showed the same pattern of alternative splicing, skipping exon 4 to induce a PTC, as seen in the human CLKs. The significance of this evolutionary conservation is underscored by the recent finding that low-abundance alternative exons are \'mostly not conserved\' between human and mouse \[[@B50]\]. For the CLK genes, the alternative exons and the introns flanking them are among the most similar regions of these genes (Figure [5b](#F5){ref-type="fig"}).

We next searched for evidence of more distant conservation of CLK alternative splicing. We identified the single CLK homolog in the sea squirt by using a hidden Markov model of CLKs to search the *Ciona intestinalis*genome (see Materials and methods). EST evidence clearly indicated that the same alternative splicing pattern seen in human and mouse is also conserved in *C. intestinalis*. We were not able to observe a set of similar splicing patterns in *D. melanogaster*(data not shown).

Menegay and co-workers \"tested whether expression of CLK1 splice products was subject to regulation by cellular stressors\" \[[@B48]\]. They found that \"UV exposure or high salt conditions had no effect on the ratio of full-length to truncated splice forms of CLK1. Cycloheximide, however, had a large effect, changing the ratio dramatically in favor of the truncated kinase-less form of mRNA\" (see Figure [6](#F6){ref-type="fig"}). Cycloheximide, a chemical inhibitor of translation, is known to inhibit NMD \[[@B51]\], because NMD depends on translation. Indeed, cycloheximide is now a commonly used reagent for NMD-inhibition experiments (see, for example \[[@B28],[@B52],[@B53]\]). Combined with our finding that the \'truncated\' mRNA isoform possesses a PTC, the results of Menegay *et al*. can be readily explained: the increased abundance of the truncated PTC^+^isoform following cycloheximide treatment is likely to be the result of inhibiting NMD, which normally degrades it.

CLK1 has been shown to indirectly affect its own splicing \[[@B46]\]: the presence of high levels of CLK1 protein favors generation of the truncated PTC^+^splice variant. However, instead of coding for an inactive, truncated protein isoform, we propose that this PTC^+^mRNA isoform may be simply degraded by NMD. Autoregulation of this type would be analogous with that seen for the splicing factors SC35 \[[@B29]\] and PTB \[[@B35]\]. Both SC35 and PTB proteins promote the alternative splicing of PTC^+^isoforms of their own mRNAs, which are then degraded by NMD.

LARD/TNFRSF12/DR3/Apo3
----------------------

Death-domain-containing receptors such as LARD (also known as TNFRSF12, DR3 and Apo3; SWISS-PROT entry Q99831) are known to regulate the balance between lymphocyte proliferation and apoptosis \[[@B54]\]. The term death domain refers to a conserved intracellular region present in receptors such as Fas and tumor necrosis factor receptor 1 (TNFR-1) that is capable of inducing apoptosis when the receptor has bound its ligand (in these cases, Fas ligand and tumor necrosis factor α (TNFα) respectively). The regulation of functional death receptor expression is important in maintaining the balance between lymphocyte proliferation and apoptosis *in vivo*.

LARD is alternatively spliced to produce 12 isoforms \[[@B55]\]. There is one full-length isoform that encodes a death domain and its expression is pro-apoptotic. Many of the 11 other isoforms, whose functions are unclear, do not encode the death domain. In a study of differential expression of LARD in unstimulated and activated lymphocytes, Screaton and co-workers found that \"\...there is no change in overall LARD expression in different lymphocyte subsets\" \[[@B55]\]. Although total expression levels were unchanged, the pattern of alternative splicing changed dramatically (Figure [7](#F7){ref-type="fig"}). Unstimulated lymphocytes expressed five \'truncated\' isoforms, but very little of the full-length isoform. They found that, \"After lymphocyte activation, there is a complete switch in splicing that will expose PHA-blasted \[activated\] cells to the risk of apoptosis triggered through LARD\...The splicing pattern reverses after PHA blasting when isoforms encoding the truncated molecules are much reduced and LARD-1 predominates.\"

We found that the five truncated LARD mRNA isoforms shown expressed in unstimulated lymphocytes all have PTCs (isoforms 2, 3, 4, 5 and 6). (Note that SWISS-PROT uses a different numbering scheme in which isoforms 2-6 are known as 12, 3, 5, 6 and 7, respectively.) Only the full-length apoptosis-promoting isoform 1, expressed in activated lymphocytes, is free of a PTC. Although there is presently no evidence of transcript degradation, this precise correlation between PTC-containing isoform expression and lymphocyte activation suggests that the role of alternative splicing in regulating lymphocyte apoptosis may be mediated by NMD.

Conclusions
===========

We found that 144 of the human alternative isoforms described in SWISS-PROT derive from mRNAs that contain PTCs. These mRNAs are apparent targets for NMD, and we expect that most are degraded by this system. In many cases, existing experimental evidence is consistent with this expectation. Because our analysis was restricted to only human entries and many SWISS-PROT records could not be reliably analyzed, it is likely that there remain more unidentified putative NMD targets. We are beginning a collaborative project with SWISS-PROT to identify and suitably annotate these entries. The relevance of this effort is highlighted by the many instances in which existing experimental data can be explained in the light of NMD action.

Materials and methods
=====================

SWISS-PROT isoform extraction and assembly
------------------------------------------

We analyzed each of the 1,641 SWISS-PROT v.41 human entries containing a VARSPLIC line in its feature table \[[@B39]\]. Information contained in each VARSPLIC line was used to assemble protein isoform sequences for 4,556 isoforms from 1,636 unique SWISS-PROT entries. Five entries could not be analyzed due to ambiguous VARSPLIC annotation.

Identification of corresponding cDNA/mRNA sequences
---------------------------------------------------

Although SWISS-PROT contains cross-references to cDNA/mRNA sequences for major protein isoforms, cross-references do not exist for many alternative isoforms. To find the cDNA/mRNA sequence corresponding to each SWISS-PROT protein isoform, we used BLAST version 2.2.4 \[[@B56]\] to align each protein isoform sequence to translated cDNA/mRNA sequences from all GenBank \[[@B40]\] and RefSeq cDNA/mRNA sequences in these databases as of 22 March 2003 \[[@B41]\]. In these alignments, we required ≥ 99% identity over the full length of the SWISS-PROT isoform. In cases of multiple matches, we selected 100% identical matches over 99% identical matches and RefSeq matches over GenBank matches. For SWISS-PROT isoforms matching multiple entries from the same database at the same percent identity, the match associated with the longest cDNA/mRNA sequence was chosen. These rules associated 2,871 alternatively spliced human SWISS-PROT protein isoforms from 1,496 SWISS-PROT entries with a corresponding cDNA/mRNA sequence from either RefSeq or Genbank.

Retrieving coding sequences and genomic loci
--------------------------------------------

We used LocusLink \[[@B41]\] to map each cDNA/mRNA sequence to the correct human genomic contig sequence from the National Center for Biotechnology Information (NCBI) human genome build 30 \[[@B57]\]. The coding sequence (CDS) feature of each GenBank or RefSeq record was used to identify the location of the termination codon. Of the 2,871 alternatively spliced human SWISS-PROT protein isoforms we associated with corresponding cDNA/mRNA sequences, 2,742 had GenBank or RefSeq records that were not polycistronic, allowing us to unambiguously determine the termination codon location for these records. These 2,742 alternative isoforms represented 1,463 unique SWISS-PROT entries.

Assessing NMD candidacy
-----------------------

The SPIDEY mRNA-to-genomic DNA alignment program \[[@B42]\] was used to determine the location of introns in each cDNA/mRNA alternative isoform sequence. SPIDEY takes as input a cDNA/mRNA sequence and the corresponding genomic sequence, and it generates an alignment that establishes the gene structure. Of the 2,742 alternatively spliced human SWISS-PROT protein isoforms for which both a cDNA/mRNA sequence and stop codon location could be identified, 2,483 resulted in high-confidence SPIDEY alignments, leading us to discard 259 from our analysis. These 2,483 isoform sequences represented 1,363 unique SWISS-PROT entries. We compared the intron positions to the position of the termination codon for each remaining cDNA/mRNA alternative isoform sequence. If the termination codon was found to be more than 50 nucleotides upstream of the final intron, we deemed the transcript to be PTC^+^and a candidate target for NMD according to the model of mammalian PTC recognition \[[@B14]\]. One hundred and seventy-seven alternatively spliced human isoforms from 130 SWISS-PROT entries were identified as possible PTC^+^splice variants using these criteria. These predictions required further screening, however, to confirm the veracity of the SPIDEY alignments on which they were based.

We manually reviewed all 177 putatively PTC^+^alignments and discarded 33 because of demonstrable errors in the SPIDEY alignments. These errors included a variety of malformed intron predictions and poly(A) tails mistakenly annotated as 3\' exons. Isoforms that remained following the application of these manual filters were deemed high-confidence PTC^+^mRNAs. This was the case for 5.8% of the isoforms (144 of 2,483) from 7.9% of the unique SWISS-PROT entries studied (107 of 1,363). The SPIDEY alignment for each of these is included in Additional data file 1; the sequence identifiers for each step are included in Additional data file 2.

CLK analysis
------------

Human CLK1, CLK2 and CLK3 (SWISS-PROT IDs P49759, P49760, and P49761) were among those SWISS-PROT entries we selected for further examination. They were mapped to RefSeq and GenBank entries, as shown in Figure [2](#F2){ref-type="fig"}. LocusLink was used to associate each CLK gene sequence to its corresponding genomic contig. For each gene, SPIDEY version 1.35 was run twice, using the vertebrate splice-site setting, to align it with its contig sequence and determine its gene structure. This first SPIDEY alignment was used to define the extent of each gene\'s locus: the region containing all the coding sequence, introns, and 1,000 nucleotides of flanking sequence on each side. The second SPIDEY alignment was made using just this locus. Custom scripts (available from the authors on request), GFF2PS \[[@B58]\], and manual editing were used to generate the graphical representations of the gene structures shown in Figure [4](#F4){ref-type="fig"}. Intron and exon sequences were then extracted using the SPIDEY results to delineate exon and intron boundaries. Corresponding exons and introns were globally aligned using ALIGN version 2.0u \[[@B59]\] with default parameters.

Mouse CLKs were identified using RefSeq annotation (NM_009905 - which skipped exon 4 and had a PTC, NM_007712, and NM_007713). Genomic loci sequences were generated and gene structures determined for each mouse CLK gene using SPIDEY, as above. The loci sequences were then used to search the mouse ESTs from dbEST (1 May 2003) \[[@B60]\] using WU-BLAST 2.0MP (23 May 2003) \[[@B61]\] with default parameters. Hits with E-values of 10^-30^or better were aligned to the locus sequence using SPIDEY. These alignments were examined for evidence of PTC-inducing alternative splicing. The GI numbers for ESTs that exhibited the alternative splicing pattern shown in Figure [3](#F3){ref-type="fig"} for each of the mouse CLKs are: CLK1 (full-length): 25118521, 21852543, 12560958, and others; CLK2 (exon 4 skipping): 22822098; CLK3 (exon 4 skipping): 26079129.

The *C. intestinalis*CLK homolog was identified from the database of predicted peptides \[[@B62],[@B63]\] by searching (HMMSEARCH V2.2G) \[[@B64]\] with a HMMER model of known CLKs. This model was generated using HMMBUILD (default parameters) and calibrated using HMMCALIBRATE from a CLUSTAL W V1.83 \[[@B65]\] alignment of the following CLK sequences: NP_004062, NP_003984, NP_003983, NP_031738, BAB33079, NP_031740, NP_065717, AAH43963, NP_599167, NP_031739, NP_477275, EAA12103, NP_741928, BAB67874, and NP_850695. The most significant hit (E-value: 4.4e-243) from *C. intestinalis*was ci0100143784. Visual inspection of other, less significant hits revealed that they align with only the kinase domain of the CLK model and none contains the LAMMER motif characteristic of CLKs. A maximum-likelihood tree was generated using PROTML V2.3B3 \[[@B66]\] using ci0100143784 and the three full-length human CLKs. This tree revealed that the *C. intestinalis*CLK is orthologous to human CLK2. The corresponding cDNA transcript sequence, ci0100143784, was retrieved from the database of predicted transcripts \[[@B67]\].

As above, the locus for this gene was extracted from the genomic contig sequence, Scaffold18, and used to search the database of *C. intestinalis*ESTs. The following ESTs showed the full-length pattern with no PTC: 24144377, 24820603, 24627564, 24627468, 24866887, and 2482449. The following ESTs showed the alternatively spliced pattern that generates a PTC: 24888181, 24606693, 24823992, and 24893089.

The *C. intestinalis*CLK gene was found to have only 11 exons, whereas human and mouse CLK2 have 13. To determine which exons were homologous, we generated a CLUSTALW multiple-sequence alignment of the known CLK protein sequences listed above and *C. intestinalis*CLK and used this alignment to identify corresponding regions of DNA sequence. This unambiguously indicated the exon-to-exon alignment shown in Figure [4](#F4){ref-type="fig"}.

Additional data files
=====================

A table showing the raw SPIDEY output of the 144 NMD-candidate isoform genes (Additional data file [1](#s1){ref-type="supplementary-material"}) and a file containing the identifiers of sequences at each major step of the analysis pipeline (Additional data file [2](#s2){ref-type="supplementary-material"}) are available.

Supplementary Material
======================

###### Additional data file 1

A table showing the raw SPIDEY output of the 144 NMD-candidate isoform genes

###### 

Click here for additional data file

###### Additional data file 2

A file containing the identifiers of sequences at each major step of the analysis pipeline

###### 

Click here for additional data file
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Figures and Tables
==================

![Recognition of premature termination codons in humans is splicing dependent. **(a)**During pre-mRNA processing, introns are removed and a set of proteins called the exon-junction complex is deposited. According to the current model for mammalian NMD, these complexes serve to facilitate transport from the nucleus and to remember the gene structure. During the first, pioneering, round of translation, the ribosome will displace all exon-junction complexes in its path until it reaches a stop codon. If the termination codon is on or near the final exon, as is the case for most genes, the ribosome will have displaced all exon-junction complexes. The mRNA will then undergo multiple rounds of translation. **(b)**If the termination codon is sufficiently far upstream of the final intron position, exon-junction complexes will remain. Interactions ensue that result in the degradation of the mRNA by NMD.](gb-2004-5-2-r8-1){#F1}

![Many human alternative isoforms in SWISS-PROT derive from PTC^+^mRNAs. **(a)**We analyzed each of the human SWISS-PROT entries containing a VARSPLIC line in its feature table, using this information to assemble protein isoform sequences. Ambiguous VARSPLIC entries led us to discard five entries from our analysis at this point. **(b)**We next identified cDNA/mRNA sequences corresponding to each protein isoform assembled from SWISS-PROT. BLAST was used to align each protein isoform sequence to translated cDNA/mRNA sequences in GenBank and Refseq, filtering to ensure only high confidence matches. To obtain the coding sequence of each mRNA/cDNA sequence, we used LocusLink to map each to the correct human genomic contig sequence from the NCBI human genome build 30. We referred to the CDS feature of each GenBank or RefSeq cDNA/mRNA record to identify stop codon locations. **(c)**We used the SPIDEY mRNA-to-genomic DNA alignment program to determine the gene structure of each mRNA/cDNA isoform sequence. After generating these gene structures, we could determine the PTC^+^status on the basis of stop codon location relative to exon-exon junctions. If the termination codon was found to be more than 50 nucleotides upstream of the final intron, the transcript was deemed PTC^+^and designated a candidate target of NMD according to the model of mammalian PTC recognition. **(d)**Each putative PTC^+^isoform was manually inspected for errors in gene structure prediction. These errors include false exon predictions due to poly(A) tails and cDNA/mRNA sequence not seen in the corresponding genomic sequence.](gb-2004-5-2-r8-2){#F2}

![SWISS-PROT entries with multiple isoforms amenable to analysis generate more PTC^+^isoforms. We categorized SWISS-PROT entries by the number of isoforms that are amenable to our analysis, and we then determined how many contained a PTC. Each bar shows the number of PTC^+^isoforms generated for all SWISS-PROT entries that had the indicated number of isoforms amenable to analysis. Bar components indicate how many entries had a given number of PTC^+^isoforms. For example, the bar labeled \'3\' contains data for the 113 SWISS-PROT entries that had 3 isoforms amenable to analysis. 86% of these had no PTC+ isoforms, 10% had one PTC^+^isoform, and 4% had 2 PTC^+^isoforms. The bar components outlined in green were SWISS-PROT entries for which all amenable isoforms had a PTC. Entries with multiple isoforms amenable to analysis were more likely to produce at least one PTC^+^isoform. This study only considered entries with at least two isoforms in the SWISS-PROT database. For many entries only a single isoform is amenable to analysis, however.](gb-2004-5-2-r8-3){#F3}

![Published expression levels of calpain-10 isoforms are consistent with NMD prediction. **(a)**A report from Horikawa and co-workers \[[@B43]\] found eight alternative isoforms of calpain-10, of which four are expressed in low abundance. Our analysis found this exact set of four low-abundance isoforms to contain PTCs. **(b)**Gene structures of alternative mRNA isoforms of calpain-10 show the patterns of alternative splicing and indicate locations of PTCs. Also shown is the position of UCSNP-43, an intronic polymorphism that has been statistically linked to type II diabetes susceptibility in a variety of populations.](gb-2004-5-2-r8-4){#F4}

![Splicing to generate a premature termination codon is evolutionarily conserved in CLKs. The CDC-like kinases (CLKs) are splicing regulators that affect splicing decisions through the phosphorylation of SR proteins. **(a)**Our screen of SWISS-PROT revealed that human CLK1, CLK2 and CLK3 paralogs all generate PTC^+^alternative isoforms. The splicing pattern that generates these isoforms, skipping exon 4, is conserved in each. This splicing pattern causes a frameshift and a PTC. The percent identities from global alignments between corresponding exons and introns are shown in purple. **(b)**CLKs were identified in mouse through existing annotation and in the predicted genes of the sea squirt *C. intestinalis*using an HMM constructed with annotated CLKs from a variety of organisms. An EST analysis revealed that the alternative splicing pattern that generates PTC^+^alternative isoforms was conserved in all three sets of orthologs in human and mouse. The same splicing pattern was also found in the only *C. intestinalis*homolog. A relatively high degree of sequence similarity was found to be present in the introns flanking the alternative exon.](gb-2004-5-2-r8-5){#F5}

![Cycloheximide increases abundance of CLK1 PTC^+^isoform. **(a)**Gene structures of CLK1 full-length and PTC+ isoforms as determined by our analysis. **(b)**Menegay *et al*. \[[@B48]\] performed the RT-PCR analysis of CLK1 isoforms; Figure 8 of that analysis \[[@B48]\] is reproduced here with permission (^©^Company of Biologists Ltd.). The 560 bp fragment corresponds to the full-length CLK1 isoform; the 453 bp fragment corresponds to the PTC^+^CLK1 isoform. The analysis shows that cycloheximide, but not UV irradiation or high salt (data not shown), increased the relative abundance of the CLK1 isoform containing a premature termination codon. As cycloheximide is a potent inhibiter of NMD (see, for example, \[[@B28],[@B51]-[@B53]\]), this result suggests that the CLK1 PTC^+^isoform is degraded by NMD. Menegay *et al*. \[[@B48]\] describe their figure as follows: \"Shift in PCR products of splice forms with cycloheximide. Control or PC12 cells treated with 10 μg/ml cycloheximide for 60 minutes were harvested, RNA was extracted, and RT-PCR was performed. \[\...\] PCR products of the 560 bp full-length form or the 453 kinase-less form of CLK1 message shown. \[\...\] PCR of GAPDH controls from each sample to control for RNA loading.\"](gb-2004-5-2-r8-6){#F6}

![LARD/TNFRSF12/DR3/Apo3 expression correlates with PTC^+^status. LARD is an alternatively spliced death-domain-containing member of the tumor necrosis factor receptor family (TNFR). However, only the major splice variant (isoform 1) contains the death domain and is capable of inducing apoptosis. The splicing distribution of LARD isoforms has been shown to change on lymphocyte activation, suggesting that alternative splicing may be a control point regulating lymphocyte proliferation \[[@B55]\]. **(a)**Screaton *et al*. \[[@B55]\] showed that, before lymphocyte activation, only LARD isoforms 2, 3, 4, 5 and 6 are expressed. Primary blood lymphocytes treated with an activating agent were found instead to express the major, apoptosis-promoting splice variant (isoform 1) almost exclusively. This panel is reproduced with permission from Figure 6a of \[[@B55]\] (^©^National Academy of Sciences). Screaton *et al*. \[[@B55]\] describe their figure as follows: \"Southern blots of reverse transcriptase-PCR of LARD cDNA with primers F LARD Kpn and R LARD Xba probed with 32P-labeled primer F LARD Xba. Lanes: 1, CD4^+^cells; 2, CD8^+^cells; 3, B cells; 4 PHA-blasted PBL; 5, negative control.\" **(b)**LARD isoforms 2, 3, 4, 5 and 6 were found in our analysis of SWISS-PROT to have PTCs, rendering them potential targets of NMD. The precise correlation between LARD isoform expression and PTC^+^status hints that there may be a role for alternative-splicing-induced NMD. Here, the gene structures of these five isoforms are shown alongside that of the full-length LARD isoform (isoform 1). In each case, the location of the stop codon has been labeled and, where appropriate, isoforms have been denoted as PTC^+^.](gb-2004-5-2-r8-7){#F7}

###### 

NMD-candidate SWISS-PROT isoforms

  Accession number   SWISS-PROT ID    Isoform name   Gene name(s)                                         cDNA/mRNA
  ------------------ ---------------- -------------- ---------------------------------------------------- ---------------
  P78314             3BP2_HUMAN       SHORT          SH3BP2; 3BP2; RES4-23                                AB000463
  P05023             A1A1_HUMAN       SHORT          ATP1A1                                               U16798
  Q9NSE7             ABCD_HUMAN       2              ABCC13                                               AF418600
                                      3                                                                   NM_138726
  O75078             AD11_HUMAN       SHORT          ADAM11; MDC                                          NM_021612
  Q9P0K1             AD22_HUMAN       2              ADAM22; MDC2                                         NM_021722
  Q9Y6N9             AI75_HUMAN       3              USH1C; AIE75                                         AF039699
  Q92667             AKP1_HUMAN       2              AKAP1; AKAP149                                       NM_139275
  P20594             ANPB_HUMAN       SHORT          NPR2; ANPRB                                          NM_000907
  P18847             ATF3_HUMAN       2              ATF3                                                 NM_004024
  Q9H6X2             ATR1_HUMAN       MAJOR          ANTXR1; ATR; TEM8                                    NM_032208
  Q9NY97             B3G7_HUMAN       2              B3GNT1; B3GALT7                                      AF288209
  Q9HB09             BC12_HUMAN       2              BCL2L12; BPR                                         NM_052842
  P13497             BMP1_HUMAN       BMP1 6         BMP1                                                 NM_006130
                                      BMP1 5                                                              NM_006131
                                      BMP1 4                                                              NM_006132
  Q9HB55             C343_HUMAN       4              CYP3A43                                              AF280111
  P01258             CAL0_HUMAN       2              CALCA; CALC1                                         M64486
  **Q9HC96**         **CANA_HUMAN**   **B**          **CAPN10; KIAA1845**                                 **NM_023084**
                                      **D**                                                               **NM_023086**
                                      **E**                                                               **NM_023087**
                                      **F**                                                               **NM_023088**
  P28907             CD38_HUMAN       2              CD38                                                 D84277
  Q08722             CD47_HUMAN       OA3 305        CD47                                                 BC037306
  O15519             CFLA_HUMAN       9              CFLAR; CLARP; MRIT; CASH                             AF009617
  Q9H2X0             CHRD_HUMAN       3              CHRD                                                 AF209930
                                      4                                                                   AF283325
  O43526             CIQ2_HUMAN       3              KCNQ2                                                NM_004518
  Q9NYG8             CIW4_HUMAN       2              KCNK4; TRAAK                                         NM_016611
  **P49759**         **CLK1_HUMAN**   **SHORT**      **CLK1; CLK**                                        **L29222**
  **P49760**         **CLK2_HUMAN**   **SHORT**      **CLK2**                                             **NM_001291**
  **P49761**         **CLK3_HUMAN**   **2**          **CLK3**                                             **NM_001292**
  Q13286             CLN3_HUMAN       4              CLN3; BTS                                            AF077963
  Q99788             CML1_HUMAN       MAJOR          CMKLR1; DEZ; CHEMR23                                 U79526
  P27815             CN4A_HUMAN       2              PDE4A                                                AF069491
  Q9H9E3             COG4_HUMAN       2              COG4                                                 AB088369
  Q9Y215             COLQ_HUMAN       VII            COLQ                                                 NM_080543
  Q96SM3             CPXM_HUMAN       2              CPXM                                                 BC032692
  Q9BZJ0             CRN1_HUMAN       4              CRNKL1; CRN                                          AF318304
                                      5                                                                   AF318305
  Q9BUV8             CT24_HUMAN       4              C20ORF24                                             BC004446
  P57077             CU07_HUMAN       B              C21ORF7                                              AF269162
                                      C                                                                   AF269163
  Q9NVD3             CU18_HUMAN       B              C21ORF18                                             AF391112
  Q92879             CUG1_HUMAN       MAJOR          CUGBP1; BRUNOL2; CUGBP; NAB50                        AF248648
  O76075             DFFB_HUMAN       BETA           DFFB; DFF2; DFF40; CAD                               AB028911
                                      GAMMA                                                               AB028912
                                      DELTA                                                               AB028913
  P25686             DJB2_HUMAN       3              DNAJB2; HSJ1; HSPF3                                  NM_006736
                                      MAJOR                                                               S37374
  Q09013             DMK_HUMAN        11             DMPK; MDPK                                           L19268
  Q9NYP3             DONS_HUMAN       2              DONSON; C21ORF60                                     NM_145794
                                      3                                                                   NM_145795
  Q9NY33             DPP3_HUMAN       2              DPP3                                                 NM_130443
  O60941             DTNB_HUMAN       3              DTNB                                                 NM_033147
  P29320             EPA3_HUMAN       MAJOR          EPHA3; ETK1; ETK; HEK                                NM_005233
  O75616             ERAL_HUMAN       HERA B         ERAL1; HERA                                          AF082658
  Q92731             ESR2_HUMAN       3              ESR2; NR3A2; ESTRB                                   BC024181
  O00507             FAFY_HUMAN       SHORT          USP9Y; USP10; DFFRY                                  Y13619
  P24071             FCAR_HUMAN       B DELTA S2     FCAR; CD89                                           NM_133280
  P41439             FOL3_HUMAN       SHORT          FOLR3                                                Z32633
  O95954             FTCD_HUMAN       E              FTCD                                                 AF289024
  P59103             G72_HUMAN        MAJOR          G72                                                  AY138546
                                      2                                                                   NM_172370
  Q9UBA6             G8_HUMAN         MAJOR          C6ORF48; G8                                          NM_016947
  Q9UBS5             GBR1_HUMAN       1E             GABBR1                                               NM_021905
  Q9BSJ2             GCP2_HUMAN       2              TUBGCP2; GCP2                                        BC005011
  P56159             GDNR_HUMAN       2              GFRA1; GDNFRA; TRNR1; RETL1                          NM_145793
  O94925             GLSK_HUMAN       GAC            GLS; KIAA0838                                        AF158555
  Q969S8             HD10_HUMAN       4              HDAC10                                               AL022328
  Q30201             HFE_HUMAN        MAJOR          HFE; HLAH                                            NM_000410
  Q9NRM6             I17S_HUMAN       2              IL17RB; IL17BR; EVI27                                NM_172234
  Q14790             ICE8_HUMAN       7              CASP8; MCH5                                          NM_033357
  Q92851             ICEA_HUMAN       B              CASP10; MCH4                                         NM_001230
                                      C                                                                   NM_032976
  Q92985             IRF7_HUMAN       C              IRF7                                                 NM_004030
  Q01638             IRL1_HUMAN       C              IL1RL1; ST2; T1; DER4                                NM_173459
  O14713             ITP1_HUMAN       MAJOR          ITGB1BP1; ICAP1                                      NM_004763
                                      2                                                                   NM_022334
  Q9HCP0             KC11_HUMAN       1S             CSNK1G1                                              NM_022048
  P20151             KLK2_HUMAN       3              KLK2                                                 AF188745
  Q9H2R5             KLKF_HUMAN       2              KLK15                                                NM_023006
  Q9UJU2             LEF1_HUMAN       B              LEF1                                                 AF294627
  P19256             LFA3_HUMAN       SHORT          CD58; LFA3                                           X06296
  P53667             LIK1_HUMAN       3              LIMK1; LIMK                                          NM_016735
  Q99698             LYST_HUMAN       MAJOR          CHS1; LYST; CHS                                      NM_000081
  P49641             M2A2_HUMAN       SHORT          MAN2A2; MANA2X                                       NM_006122
  O95405             MADI_HUMAN       2              MADHIP; SARA                                         NM_007324
  P11137             MAP2_HUMAN       MAJOR          MAP2                                                 NM_002374
                                      MAP2C                                                               NM_031845
  P27816             MAP4_HUMAN       2              MAP4                                                 BC015149
  P25912             MAX_HUMAN        3              MAX                                                  NM_145113
  Q15759             MK11_HUMAN       BETA 2         MAPK11; PRKM11; SAPK2                                NM_002751
  O15438             MRP3_HUMAN       3A             ABCC3; CMOAT2; MRP3; MLP2                            NM_020037
                                      3B                                                                  NM_020038
  P21757             MSRE_HUMAN       II             MSR1                                                 NM_002445
  Q9H1B4             NXF5_HUMAN       MAJOR          NXF5; TAPL1                                          NM_032946
                                      B                                                                   NM_033152
                                      C                                                                   NM_033153
                                      D                                                                   NM_033154
                                      E                                                                   NM_033155
  Q96QS1             PHMX_HUMAN       5              PHEMX; TSSC6                                         NM_139023
                                      4                                                                   NM_139024
  O14829             PPE1_HUMAN       2              PPEF1; PPEF; PPP7C                                   NM_152225
  Q9UMR5             PPT2_HUMAN       2              PPT2                                                 NM_138934
  Q9NQW5             PRD7_HUMAN       MAJOR          PRDM7; PFM4                                          NM_052996
  O14818             PSA7_HUMAN       4              PSMA7                                                NM_152255
  P55036             PSD4_HUMAN       RPN10E         PSMD4; MCB1                                          NM_153822
  P49768             PSN1_HUMAN       I 374          PSEN1; PSNL1; AD3; PS1                               NM_007319
  P23468             PTPD_HUMAN       MAJOR          PTPRD                                                NM_002839
  O75771             R51D_HUMAN       2              RAD51L3; RAD51D                                      NM_133627
  Q93062             RBMS_HUMAN       MAJOR          RBPMS                                                NM_006867
  P78563             RED1_HUMAN       MAJOR          ADARB1; RED1; DRADA2                                 NM_015833
  O15126             SCA1_HUMAN       2              SCAMP1; SCAMP                                        NM_052822
  Q13243             SFR5_HUMAN       SRP40 2        SFRS5; SRP40; HRS                                    NM_006925
  O60902             SHX2_HUMAN       MAJOR          SHOX2; SHOT; OG12X                                   NM_006884
  Q13425             SNB2_HUMAN       2              SNTB2; SNT2B2                                        NM_130845
  Q9Y5W8             SNXD_HUMAN       2              SNX13; KIAA0713                                      NM_015132
  P18583             SON_HUMAN        E              SON; NREBP; DBP5; C21ORF50; KIAA1019                 NM_058183
                                      C                                                                   NM_138926
  Q15528             SUR5_HUMAN       SURF5A         SURF5; SURF-5                                        NM_006752
  O14763             T10B_HUMAN       MAJOR          TNFRSF10B; DR5; TRAILR2; TRICK2; KILLER; ZTNFR9      NM_003842
                                      SHORT                                                               NM_147187
  Q9BZY9             TM31_HUMAN       BETA           TRIM31                                               NM_052816
  P25445             TNR6_HUMAN       4              TNFRSF6; APT1; FAS; FAS1                             NM_152873
                                      5                                                                   NM_152875
                                      3                                                                   NM_152876
                                      2                                                                   NM_152877
  P00750             TPA_HUMAN        SHORT          PLAT                                                 NM_000931
  **Q93038**         **TR12_HUMAN**   **12**         **TNFRSF25; TNFRSF12; WSL1; WSL; APO3; DR3; DDR3**   **NM_148968**
                                      **4**                                                               **NM_148969**
                                      **3**                                                               **NM_148971**
                                      **5**                                                               **NM_148972**
                                      **6**                                                               **NM_148973**
                                      **7**                                                               **NM_148974**
  Q9BYM8             U7I3_HUMAN       4              UBCE7IP3; C20ORF18; XAP4                             NM_031227
                                      2                                                                   NM_031228
  P58418             USH3_HUMAN       B              USH3A                                                NM_174880
  Q9NP71             WS14_HUMAN       5              WBSCR14; MIO                                         NM_032994
  Q02040             XE7_HUMAN        SHORT          (XE7X; XE7; DXYS155E); (XE7Y; XE7; DXYS155E)         NM_005088
  Q9Y493             ZAN_HUMAN        1              ZAN                                                  NM_173055
                                      2                                                                   NM_173056
                                      4                                                                   NM_173057
                                      5                                                                   NM_173058

The 144 alternatively spliced human protein isoforms from SWISS-PROT V.41 whose mRNA transcripts contain premature-termination codons are listed. The SWISS-PROT accession number, SWISS-PROT identifier, gene name(s), and cDNA/mRNA sequence for each isoform are given. Isoforms discussed in the text are in bold. Isoforms labeled \"MAJOR\" are those whose sequence is displayed in SWISS-PROT for that entry. These isoforms are not necessarily the most abundant.
